GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To start a question, please ...

Core Insights - GeneDx Holdings Corp. reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, and showing a significant increase from $0.04 per share a year ago, resulting in an earnings surprise of +75.00% [1] - The company achieved revenues of $116.74 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 12.47% and increasing from $76.87 million year-over-year [2] - GeneDx Holdings has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.51 on revenues of $116.5 million, and for the current fiscal year, it is $1.56 on revenues of $410.1 million [7] Industry Context - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

GeneDx (Nasdaq: WGS) 3Q 2025 Earnings Presentation October 28, 2025 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expected full year 2025 reported revenue, growth in exome and genome revenue and volume, adjusted gross margin and a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission file number 001-39482 GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Delaware 85-1966622 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 333 Ludlow Street, North Tower; 6th Floor Stamford, Connecti ...

Financial Performance - Reported revenues for Q3 2025 were $116.7 million, representing a 52% year-over-year increase[8] - Exome and genome test revenue reached $98.9 million, a 65% increase year-over-year, with test volume growing to 25,702, up 33% year-over-year[7] - Total revenue for Q3 2025 was $116.743 million, up 52.0% from $76.874 million in Q3 2024[27] - Diagnostic test revenue for Q3 2025 reached $113.523 million, a 46.5% increase from $77.418 million in Q3 2024[27] - Adjusted net income for Q3 2025 was $14.7 million, compared to $2.0 million in Q3 2024, while GAAP net loss was $7.6 million[9] - The net loss for Q3 2025 was $7.635 million, a slight improvement from a net loss of $8.312 million in Q3 2024[27] - Basic and diluted loss per share for Q3 2025 was $0.27, compared to $0.31 in Q3 2024[27] - Net loss for the nine months ended September 30, 2025, was $3.355 million, a significant improvement from a net loss of $57.724 million in the same period of 2024[29] Margins and Expenses - Adjusted gross margin expanded to 74%, up from 64% in Q3 2024, while GAAP gross margin was 72%[5] - Gross profit for Q3 2025 was $84.527 million, resulting in a gross margin of 72.4%, compared to a gross margin of 62.2% in Q3 2024[27] - Research and development expenses increased to $19.829 million in Q3 2025, up from $11.665 million in Q3 2024, reflecting a 70.0% increase[27] - Stock-based compensation expense rose significantly to $22.382 million from $6.293 million in the prior year[29] - The company reported a depreciation and amortization expense of $18.343 million, up from $16.395 million in the previous year[29] Cash and Assets - Cash position as of September 30, 2025, was $156.1 million, with $8.8 million in free cash flow generated during Q3 2025[12] - Total current assets as of September 30, 2025, were $237.583 million, an increase from $197.968 million as of December 31, 2024[25] - Total assets increased to $493.902 million as of September 30, 2025, compared to $419.380 million as of December 31, 2024[25] - Cash, cash equivalents, and restricted cash at the end of the period totaled $96.958 million, up from $58.881 million at the end of the previous year[29] - Net cash provided by operating activities was $36.369 million, compared to a net cash used of $25.313 million in the prior year[29] Liabilities and Equity - Total liabilities as of September 30, 2025, were $201.644 million, up from $174.133 million as of December 31, 2024[25] - Stockholders' equity increased to $292.258 million as of September 30, 2025, compared to $245.247 million as of December 31, 2024[25] Business Developments - GeneDx is the sole commercial testing provider for new genomic newborn screening programs, including the NIH BEACONS initiative[7] - FDA granted Breakthrough Device Designation for GeneDx ExomeDx™ and GenomeDx™ tests, enhancing the company's leadership in genomic medicine[14] - Introduced GeneDx Infinity, the largest rare disease dataset, which supports the ExomeDx™ and GenomeDx™ tests[13] - Expanded coverage of whole genome sequencing with California Medicaid, increasing access to testing in the most populous state[13] Guidance and Future Outlook - Full year 2025 revenue guidance raised to between $425 million and $428 million, with expected growth in exome and genome revenue between 53% to 55%[11] - The company incurred $33.195 million for the acquisition of a business, net of cash acquired[29] - Proceeds from offerings, net of issuance costs, amounted to $25.568 million, an increase from $14.589 million in the prior year[29] - Cash paid for interest was $4.835 million, slightly down from $5.035 million in the previous year[29] - Cash paid for taxes increased to $1.039 million from $910,000 in the prior year[29] - The company experienced a change in accounts receivable of $(22.799) million, compared to $(5.850) million in the previous year[29]

Core Insights - GeneDx Holdings Corp. reported strong financial results for Q3 2025, highlighting significant growth in revenue and test volumes, alongside improved gross margins [2][4][7]. Financial Performance - Revenues reached $116.7 million, marking a 52% increase year-over-year [8]. - Exome and genome test revenue grew to $98.9 million, reflecting a 65% year-over-year increase [8]. - Adjusted gross margin expanded to 74%, up from 64% in Q3 2024, while GAAP gross margin was reported at 72% [4][8]. - Adjusted net income for Q3 2025 was $14.7 million, compared to $2.0 million in the same quarter of 2024 [5][8]. Operational Highlights - The volume of exome and genome tests increased to 25,702, a 33% year-over-year growth [8]. - Exome and genome tests accounted for 43% of all tests performed, up from 33% in Q3 2024 [8]. - Adjusted total operating expenses were $71.2 million, representing 61% of revenue, a slight decrease from 62% in Q3 2024 [8]. Strategic Developments - GeneDx received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, emphasizing its innovative leadership in genomic diagnostics [3][7]. - The company is leading in genomic newborn screening, being the sole commercial testing provider for new programs, including the NIH BEACONS initiative [7][13]. - GeneDx introduced GeneDx Infinity™, the largest rare disease dataset, enhancing its capabilities in rare disease insights [13][15]. Guidance and Future Outlook - GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, with expected growth in exome and genome revenue between 53% to 55% [7][9]. - The company anticipates continued volume growth of at least 30% for exome and genome tests [9].

Core Insights - GeneDx Holdings Corp. reported strong financial results for Q3 2025, highlighting significant growth in genomic testing and improved profitability metrics [2][7][8] - The company received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, emphasizing its leadership in genomic medicine [3][7][24] Financial Performance - Revenues reached $116.7 million, representing a 52% year-over-year increase [8] - Exome and genome test revenue grew to $98.9 million, a 65% increase year-over-year [8] - Adjusted gross margin expanded to 74%, up from 64% in Q3 2024, while GAAP gross margin was reported at 72% [4][8] - Adjusted net income for Q3 2025 was $14.7 million, compared to $2.0 million in Q3 2024, while GAAP net loss was $7.6 million [5][8] Operational Highlights - The volume of exome and genome tests increased by 33% year-over-year, totaling 25,702 tests [8] - Adjusted total operating expenses were $71.2 million, representing 61% of revenue, a slight decrease from 62% in Q3 2024 [8] - The company ended the quarter with a cash position of $156.1 million, including $8.8 million in free cash flow generated [8] Strategic Initiatives - GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, with expected growth in exome and genome revenue between 53% to 55% [7][9] - The company is leading genomic newborn screening initiatives, including participation in the NIH BEACONS initiative and a partnership with Florida's Sunshine Genetics Network [13] - GeneDx introduced GeneDx Infinity™, the largest rare disease dataset, enhancing its genomic testing capabilities [13][15] Market Position - GeneDx is positioned as a leader in genomic newborn screening, being the sole commercial testing provider for new programs [7][13] - The company is actively expanding its market presence and investing in sustainable growth with attractive margins [6][7]

BREAKING: Futures Mixed On Trump Comments; Fed, Huge Earnings Due Genetic testing leader GeneDx Holdings (WGS) is Monday's pick for IBD 50 Growth Stocks To Watch. The medical services stock is climbing in a seven-week-long consolidation pattern as the company's earnings report approaches. GeneDx turned profitable in 2024, and analysts expect meteoric earnings growth for its third quarter. The IBD 50 genetics testing stock was recently highlighted as an IBD Breakout… Take a Trial Today Get instant access to ...